Rick,
Here's one attempt at a "bounce" portfolio. These are mostly companies with plenty of cash and clearly-identified products either already on the market or likely to be shortly. My guess is that the funds will buy these before they venture down into T/FIF land, and so they are likely to advance first:
SEPR - I'm still a huge long-term (4-5 year) bull on this one. In the short-term it may be vulnerable to a correction given its sharp rise, but long-term it has a ways to go. I've had very good luck to date buying the furthest-out, highest-strike-price calls when it takes one of its periodic scary dips on no news.
PCYC - more speculative than the rest of these stocks because it's products are further out. This is another 4-5 year time horizon with tremendous prospects if things work out. I'm a voice in the wilderness on this one, and I know you have management concerns here.
INCY - great company, beaten down.
BGEN - earnings are coming along nicely, and some exciting stuff in their pipeline.
MLNM - Solid, long-term genomics play.
CNTO - real products, recent ReoPro news was great, and I suspect that we will see good synergy between ReopPro and Retavase, both in how they work together and in selling them.
PGNS - a Jim Silverman favorite. Again a good product with a decent pipeline and a beaten-down stock.
GELX - another Jim selection, for similar reasons to PGNS.
AVIR - short term depends on whether they get approval for this flu season or next.
AGPH - I think the tracking stock will convince the shorts to run, and will demonstrate to the street that this is cheap.
NXTR - another proposed spin-off, with real earnings that the street is currently discounting.
I own all of the above, plus some T/FIF-type stocks like BTRN and SIBI, together with some that don't really fit either portfolio, like MOGN and SNAP. I also remain partially hedged, with calls written against the BTK index and a few shorts.
Peter |
